HD-OPM Archive
Topics › Cancer

Personalized mRNA melanoma vaccine could extend to other cancers, with trials ongoing

Louis Nervegna · Aug 20, 2026 · ♥ 15 reactions · 4 comments · original Facebook post
CancerInfections & vaccines
AI summary & key facts

Louis adds that the real promise of the personalized mRNA vaccine is its use across cancers beyond melanoma. The shared physician explanation stresses it treats cancer after tumor removal rather than preventing it. Trials are ongoing in non-small cell lung, kidney and bladder cancer.

The real promise here is its application to all different kinds of cancers… beyond just melanoma.

There are on-going clinical trials in non-small cell lung cancer, as well as in kidney cancer and bladder cancer.

Also see this previous post:
facebook.com/share/v/1ZKcJLWSLk

#melanomaHD #cancerHD #mrnaHD #vaccinesHD #merckHD #modernaHD

Moderna's cancer "vaccine" made history this week, and most people misunderstand what it actually is. Three things to know, from a physician.

It doesn't prevent cancer. It treats it!!!

The word "vaccine" is misleading here. This isn't a shot that stops you from getting melanoma — it's given after the tumor is surgically removed, to clear the microscopic cancer cells left behind and stop them from returning or spreading. Here's how it's built: doctors sequence the DNA of your specific tumor, compare it to your healthy cells, and identify the mutations unique to your cancer. Machine learning ranks roughly 34 of those mutations as the best targets. Those get encoded into mRNA, which instructs your cells to display those markers so your immune system's T cells learn to recognize and attack any cell carrying them. Same mRNA platform as the COVID shots — completely different job. And it predates both COVID and the AI boom: Merck and Moderna began this program in 2016 and were dosing patients in 2017.

It only works combined with Keytruda — and that combination just passed Phase 3.

The vaccine is never used alone. Every patient also receives Keytruda, currently the highest-revenue drug in the world. The two do different jobs: the vaccine teaches the immune system which mutations to target, and Keytruda blocks the "off switch" tumors use to evade immune attack, so the T cells can actually do their work. In the Phase 3 trial of 1,137 high-risk melanoma patients, the combination significantly reduced both recurrence and spread to distant organs versus Keytruda alone — the first Phase 3 win for any mRNA cancer therapy. Earlier-stage data had shown about a 49% reduction in recurrence or death.

Melanoma is a proof of concept for the whole platform.

The reason this matters beyond skin cancer: the method is repeatable. The same personalized process — sequence the tumor, pick the mutations, build the mRNA — can in principle be applied to other cancers. Phase 3 trials in non-small cell lung cancer are already running, with bladder and kidney behind them. And Moderna isn't the only one: BioNTech is developing nearly identical individualized mRNA therapies. Melanoma success is a strong signal for the approach, not a guarantee it works everywhere — but it's the clearest proof to date that the platform works at all.

The prior major advance in cancer treatment was immunotherapy — checkpoint inhibitors like Keytruda, which help the immune system recognize tumors it was ignoring. This is the next step: not just helping the immune system see the cancer, but training it against the specific mutations in one patient's tumor.

Twenty-four hours ago, whether this approach could work in a large trial was an open question. As of this week, the data says it does.

← newer: Urolithin A, a pomegranate gut metabolite, improved HFpEF inolder: Personalized mRNA vaccine succeeds in phase 3 melanoma trial →